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Background: Immunotherapy has been proven effective in several tumours, hence diverse
immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney
cancer, lung cancer and most recently, tumours with microsatellite instability. There is much
enthusiasm for investigating this approach in gynaecological cancers and the possibility
that immunotherapy might become part of the therapeutic landscape for gynaecological
malignancies.
Cervical cancer is the fourth most frequent cancer in women worldwide and represents
7.9% of all female cancers with a higher burden of the disease and mortality in low-
and middle-income countries. Cervical cancer is largely a preventable disease, since the
introduction of screening tests, the recognition of the human papillomavirus (HPV) as an
etiological agent, and the subsequent development of primary prophylaxis against high risk
HPV subtypes. Treatment for relapsed/advanced disease has improved over the last 5 years,
since the introduction of antiangiogenic therapy. However, despite advances, the median
overall survival for advanced cervical cancer is 16.8 months and the 5-year overall sur-
vival for all stages is 68%. There is a need to improve outcomes and immunotherapy could
offer this possibility. Clinical trials aim to understand the best timing for immunotherapy,
either in the adjuvant setting or recurrent disease and whether immunotherapy, alone or
in combination with other agents, improves outcomes.
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1. Background
Cervical cancer is the fourth most frequent cancer in women
with an estimated 530,000 new cases representing 7.9% of
all female cancers.1 85% of the global burden occurs in low-
and middle-income economies, where it accounts for almost
12% of all female cancers.2 Cervical cancer is rare before
age 20, however it affects a younger population of women
with a median age at diagnosis of 49 years.3 Cervical cancer
causes 270,000 deaths annually and mortality varies 18-fold
between different regions of the world, with rates ranging
from less than 2 per 100,000 in Western Asia, Western Europe
and Australia/New Zealand to more than 20 per 100,000 in
Melanesia, Middle and Eastern Africa.1
Although significant progress has been achieved in the
screening and prevention of cervical cancer, five-year over-
all survival remains around 60% and treatment for relapsed
disease is still challenging. For women diagnosed at an early
stage, the likelihood of recurrence is 10–20% following primary
surgery or radiotherapy, and for those with more advanced
disease, recurrence rate is up to 70% depending on the stage.4
Median overall survival (OS) for patients with recurrent dis-
ease has improved since the introduction of bevacizumab
(antiangiogenic agent) in combination with chemotherapy5
increasing the median OS to above the one year mark.
There is no specific standard of care option beyond the first
line systemic therapy, the most commonly used regimens
include weekly paclitaxel, carboplatin-based, docetaxel-based
chemotherapy, topotecan, gemcitabine and targeted therapy
within clinical trials.6 In this setting, a retrospective series
reported a response rate of 13.2%, median progression-free
survival (PFS) is 3.2 months with a median overall survival
(OS) of only 9.3 months.6 There is an urgent need for better
therapies.
The recognition of the human papilloma virus as etiolog-
ical cause of the disease has been an important milestone
in the understanding of the disease, helping to develop new
preventive strategies and improve screening.7 HPV infections
are common and the life-time risk of infection is approxi-
mately 80% for productive women, HPV life cycle is related
with their host cell biology8 and wide majority of HPV infec-
tions are cleared within 6–12 months, a minor percentage
(10–12%) remains uncleared and produced oncogenic changes
in the epithelium9 leading to pre-malignant lesions and can-
cer years after the first infection.10,11
Ninety-five percent of cases of cervical cancer are
caused by persistent infections with carcinogenic human
papillomaviruses.7 Persistent infections express viral onco-
genes E6 and E7 that inactivate p53 and retinoblastoma
protein, respectively, leading to increased genomic instabil-
ity, accumulation of somatic mutations, and in some cases,
integration of HPV into the host genome.8 There are more
than 150 HPV types identified, approximately 40 can infect
the cervix and amongst all the HPV types, twelve are classi-
fied as high risk, these include HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, and 59.12 HPV16 is the most carcinogenic in
terms of cervical cancer incidence and cervical intraepithelial
neoplasia grade 3,13,14 HPV18 is second in terms of etiologic
importance; however, it is the most important etiological
agent amongst adenocarcinomas.13
Prophylactic vaccines will not be discussed in this review;
however, it is important to mention that they provide a pro-
tective immunity against most HPV high risk subtypes, but
do not offer universal protection against HPV infection nor
are they as effective as treatment for existing HPV infection.9
The reason for this is that prophylactic vaccines target capsid
antigens and HPV-infected basal epithelial cells do not express
detectable levels of capsid antigen; hence, they are unlikely to
be effective in the elimination of established HPV infections
and HPV associated diseases.9
2. Immunotherapy for cervical cancer
The immune system plays a key role in the control of HPV
infection. The changes in the microenvironment and the
interplay between virally-infected keratinocytes and the local
immune microenvironment will determine the course of
disease in HPV-induced carcinogenesis.15 This raises the pos-
sibility that immunotherapy strategies could rebalance the
local immune factors to release existing, or generate new
and effective, antitumour immunity.16 The immune system
can be used to erradicate cancer by selective recognition of
virus-associated tumour cells17 or by releasing the negative
feedback on the cytotoxic T lymphocytes (CTLs) allowing them
to target neoplasic cells.18
2.1. Therapeutic vaccines (Table 1)
Therapeutic vaccines induce the activation and proliferation
of T cells which specifically recognize and kill cancer cells
by making use of constitutively expressed tumour-specific
antigens E6 and E7.19 For vaccines to work, the antigen
needs to be recognized by the antigen presenting cell (APC)
and then induce specific CTLs against the antigen. Different
types of vaccines have been designed for the treatment of
HPV-related cervical cancer, with varying strengths and weak-
nesses, immunogenicity and efficacy.
Live-vector vaccines are highly immunogenic and can induce
strong cellular and humoral immune responses. These vac-
cines deliver E6 and E7 antigens to APCs to stimulate antigen
presentation through the major histocompatibility complex
(MHC) class I and II.19 Limitations to this approach are the
potential safety risk, particularly in immunocompromised
individuals and the limited immune response efficacy after
repeated immunization with the same vector.20
ADXS11–001 also known as AXALTM (Advaxis) is a ther-
apeutic vaccine that uses Listeria monocytogenes (Lm) as a
bacterial vector. Lm is a gram-positive intracellular bacterium
capable of escaping the host phagosomes and, in conse-
quence, infecting the host cells; it can activate both innate
and adaptive immune responses.21 ADXS11-001 is a live-
attenuated L. monocytogenes vaccine that secretes the HPV-16
E7 antigen fused to a non-hemolytic fragment of the Lm
protein listeriolysin O (LLO).19 Lm-LLO immunotherapies do
not induce neutralizing antibodies and have the capacity to
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Table 1 – HPV therapeutic vaccines, phase I and II clinical trials.
Author/year/n Treatment schedule Response Toxicity





DL1: ADXS11-001 1 × 109
two doses every 21 days
DL2: ADXS11-001 3.3 × 109
two doses every 21 days
DL3: ADXS11-001 1 × 1010




60%, pain (57%), chills,
anaemia (53%)
Grade 3: 40% (6pts)
Ghamande et al.,
201623
Phase I recurrent or
metastatic disease
n = 9
DL1: ADXS11-001 5 × 109
three weekly during 12 wks
DL2: ADXS11-001 1 × 1010
three weekly during 12 wks
Not informed TRAE: 75%
AE: 99% grade 1–2
Grade 3: Chills, vomit,
hypotension, tachycardia,
fever and nausea.
Huh et al., 2013 (GOG
0265)24
Phase II recurrent or
metastatic disease
n = 26
ADXS11-001 1 × 109 every
28 days for 3 doses
Mean 12mo survival:
38.5%
Median OS: 6.2 mo




Grade 3 TRAE: 15% (4pts)
hypotension, cytokine
release syndrome.
Grade 4 AE: 1 pt lung
infection and sepsis.
Petit et al., 201426
Phase II recurrent or
metastatic disease
n = 109
Arm A: ADXS11-001 1 × 109
for 3 doses
Arm B: ADXS11-001 1 × 109
for 4 doses plus cisplatin
50 mg/m2 during 5 wks
ORR 11% (5CR/6PR).
DCR: 38%
OS: 8.4 mo Arm A
and 8.77 mo Arm B.
12 mo survival 32%
and 24 mo survival
18%
AE: 79% grade 1–2, mainly
flu-like symptoms
2 pts grade 3 AE





HPV16 E6 E7 SLP vaccine Vaccine enhanced
number and activity
of HPV16 specific
CD4+ and CD8+ cells






Phase II recurrent or
metastatic disease
n = 31
HPV16 E6-E7 SLP vaccine
300 g for 4 doses every 21
days













Phase I recurrent or
metastatic disease
n = 14
Arm 1: placebo 3 doses
every 14 days
Arm 2: unprimed DC 3
doses 1 × 106 cells every 14
days
Arm 3: primed DC 3 doses
1 × 106 cells every 14
SD on Arm 3 Grade 1–2: itching at
injection site, fever, chills,
abdominal discomfort,
vomit, ALP increased.
Ferrara et al., 200339











Santin et al., 200840
Phase I. Stage IB or
IIA
n = 10
DL1: HPV16/18 E7 antigen
pulsed DC 5 × 106 for 5
doses every 21 days
DL2: HPV16/18 E7 antigen
pulsed DC 10 × 106 for 5
doses every 21 days
DL3: HPV16/18 E7 antigen
pulsed DC 15 × 106 for 5
doses every 21 days
CD4+ T cell response
in all patients
Mild swelling and erythema
at the injection site.
DL: dose level; pts/pt: patients, wks: weeks; TRAE: treatment related adverse events; AE: adverse events; mo: month; OS: overall survival; ORR:
objective response rate; CR: complete response; PR: partial response; SD: stable disease; DCR: disease control rate; DC: dendritic cells.
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facilitate chemotaxis of activated immune cells as well as to
stimulate robust immune memory responses.19
Results from phase I trials22,23 have shown a safety tox-
icity profile and treatment related adverse events (TRAEs)
including pyrexia, vomiting, flu-like symptoms, muscular
pain, and hypotension. Two phase II trials with promis-
ing results have been reported. GOG-026524 studied patients
with persistent/recurrent or metastatic squamous or non-
squamous cervical cancer. Twenty-six patients were enrolled;
the mean 12-month survival was 38.5% with a median OS of
6.2 months.25 Another trial evaluated the efficacy and safety
of ADXS11-001 administered with or without cisplatin, this
phase II trial enrolled 110 patients with recurrent or progres-
sive invasive cervical cancer.26 Patients were randomized to
either 3 doses of ADXS11-001 or 4 doses of ADXS11-001 with
cisplatin. 109 patients received treatment with majority of
adverse events (AE) reported as mild or moderate. In terms of
efficacy, 12-month survival was 32%, 18-month survival was
22% and 24-month survival was 18%. The response rate was
11% and the average duration of response in both treatment
groups was 9.5 months. Overall survival was 8.4 months for
ADXS11-001 and 8.77 months for ADXS11-001 with cisplatin.
No significant differences between the response rates, disease
control rates, duration of response, or PFS were observed with
the addition of cisplatin.
Combination approaches with checkpoint inhibitors are
currently under evaluation for patients with recurrent
or metastatic HPV-related cancers, including cervical can-
cer (NCT02291055).27 In the adjuvant setting, AIM2CERV
(NCT02853604)28 a randomized phase III placebo control study,
in patients with high-risk locally advanced cervical cancer
(FIGO stage Ib2 and II with pelvic nodal involvement, FIGO
stage III and IV and any stage with para-aortic involvement),
will evaluate adjuvant ADXS11-001 following chemoradiation.
Peptide-based vaccines involve the direct administration of
peptides derived from HPV antigens for uptake by dendritic
cells (DCs), to be presented in association with MHC class I/II
molecules.29 Peptide-based vaccines are safe, stable, and rel-
atively easy to produce. However, they have relatively poor
immunogenicity and require lipids or other adjuvants, to
enhance vaccine potency.29 Phase I trials of HPV16 synthetic
long-peptide (HPV16-SLP) vaccine have demonstrated30–32 an
immune response either by itself or in combination with
chemotherapy. Toxicities did not exceed grade 2 and included
injection site pain, fever, and flu-like symptoms. The phase II
trial enrolled 21 patients with advanced or recurrent gynae-
cological cancer33; adverse events were similar to those
observed in the phase I trials. Median overall survival was 12.6
months (range 4–26 months) and median OS was 8.8 months.
HPV16-SLP vaccines are under study in combination with
chemotherapy (NCT02128126),34 and check-point inhibitors
(NCT02426892).35
Dendritic based-vaccines, DCs are leukocytes with the abil-
ity to present antigens to T cells. Isolated DCs loaded with
tumour antigen ex vivo and administered as a cellular vaccine
have been found to induce protective and therapeutic anti-
tumour immunity.36 A number of tumour-associated antigens
have been identified as potential immunogens in DC-based
vaccination strategies, including peptides that are presented
in a human leucocyte antigen (HLA) restricted fashion,
therefore available only to patients with specific HLA haplo-
types. Other tumour-associated antigens have been studied,
including tumour-derived RNA, tumour-derived apoptotic
bodies, and tumour lysates. In this case, as tumour cells
serve as a source of antigen, such vaccines are available to
all patients, irrespective of HLA type.37 Phase I trial data38–40
showed that generating loaded DCs in vitro is feasible and
this strategy is able to generate specific serologic responses
with mild toxicity. Therapeutic vaccination, including den-
dritic based-vaccines, aims to expand high-avidity CD8+ T
cells that can differentiate into CTLs able to kill cancer cells
and can generate long-lived memory CD8+T cells.41 Dendritic
cell-based vaccines have the potential to induce both tumour-
specific effector and memory T cells, yet there is a need to
improve their efficacy and the next generation of DC vaccines
is expected to generate large numbers of high-avidity effector
CD8(+) T cells and to overcome regulatory T cells41 as well as
intrinsic regulators such as CD28-CTLA-4, PD1-PDL1, and ILTs.
New strategies might include the combination of DC vaccine
with agents that target different pathways, these polyvalent
vaccines targeting distinct yet specific DC subsets are expected
to trigger a more comprehensive anti-cancer response.41
2.2. Checkpoint inhibitors (Table 2)
Checkpoint inhibitors block inhibitory receptors of immune
system elements leading to the activation of immune cells
against the tumour.42 Virus-induced cancers present a spe-
cific immunologic profile and their response to immune
checkpoint inhibitors is expected to be different than other
cancers.42 This eventual differential tumour response is a con-
sequence of a higher mutational load43 possibly leading to a
better response.42 Another possible explanation is a higher
expression of PD-L1 in virus-induced cancers;42 PD-L1 expres-
sion as a biomarker of response is controversial due in part
to the lack of clarity regarding the appropriate cut-off val-
ues quantifying clinically meaningful PD-L1 expression44 and
paucity of data showing correlation with treatment outcomes
in those with cervical cancer. Nonetheless, increased expres-
sion of PD-1 in infiltrating TILs suggests that the blockade of
PD-1/PD-L1 may have a therapeutic potential in cervical cancer
patients.45
PD-1 and PD-L1 inhibitors. Programmed cell death protein-
1/programmed death ligand-1 immune regulatory axis is
a promising target for cervical cancer treatment.44 Pem-
brolizumab (Merck Sharp & Dohme) is a humanised mon-
oclonal immunoglobulin G4 (IgG4) kappa isotype antibody
targeting PD-1. Preliminary results from the expansion cohort
of the phase Ib KEYNOTE 028 study in patients with PD-
L1-positive (≥1%) advanced solid tumours including cervical
cancer46 reported 24 patients with metastatic or unresectable
cervical squamous cell carcinoma who had failed a prior
systemic therapy. Seventy-five percent of the patients expe-
rienced a TRAE and 20.8% experienced a grade 3 TRAE. In
terms of efficacy, ORR was 12.5% and the median duration
of response was 19.3 weeks; 6-month PFS rate was 13.0%
and 6-month OS rate was 66.7%. Preliminary results from the
phase II KEYNOTE 158 trial47 included 47 recurrent/metastatic
squamous cervical cancer patients; ORR was 17% and authors
suggested that response was independent of PD-L1 status.
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Table 2 – Immune checkpoint inhibitors, phase I clinical trials.
Author/year/n Treatment schedule Response Toxicity
Frenel et al., 201646
Phase I expansion cohort,
metastatic disease
n = 24 PD-L1 IHC ≥ 1%
Pembrolizumab 10 mg/kg




6 month PFS: 13% and OS:
66.7%
75% TRAE: pyrexia, rash in
more than 10 pts





Schellens et al., 201747
Phase II, metastatic disease
n = 46
Pembrolizumab 200 mg
3weekly to 2 years
ORR 17% (87% PD-L1+)
15 pts had ≥27 wks
follow-up: ORR 27%.
Not reported
Hollebecque et al., 201752
Phase I/II recurrent or
metastatic disease
n = 24 (19 pts cervical
cancer)




Median PFS 5.5mo, OR NR
70.8% TRAEs
12.5% grade 3–4
Lheureux et al., 201559
Phase I/II recurrent or
metastatic disease
n = 42
Phase I: Ipilimumab 3 mg/kg
every 21 days for 4 doses.
Phase II: Ipilimumab
10 mg/kg every 21 days for 4
doses and 4 cycles (same
dose) every 12 weeks.
Median PFS 2.5 mo Grade 3: diarrhoea, colitis
Mayadev et al., 201760
Phase I, FIGO IB2/IIA or
IIB/IIIB/IVA, positive nodes
n = 34
Weekly cisplatin 40 mg/m2
during 6 weeks and
extended field radiotherapy.
If no progression 2–6 wks
after:
DL:1 Ipilimumab 3 mg/kg
for 4 doses every 21 days
DL2: Ipilimumab 10 mg/kg
for 4 doses every 21 days
DL3: Ipilimumab 10 mg/kg
for 4 doses every 21 days
1-year DFS: 74% Grade 1–2: rash,
endocrinopaties,
gastrointestinal toxicity.
Grade 3: 16% including
lipase increased,
neutropaenia and rash.
IHC: immunohistochemistry; ORR: objective response rate; PFS: progression free survival; OS: overall survival; TRAE: treatment related adverse
events; DCR: disease control rate; NR: not reached; DFS: disease free survival.
KEYNOTE 158 (NCT02628067) is currently recruiting patients
across different solid tumours.48
The use of pembrolizumab in first line treatment is under
evaluation in the PAPAYA trial (NCT03144466).49 This phase
I study includes patients with FIGO stage IB to IVA cervi-
cal cancer. Intravenous pembrolizumab will be followed by
radical cisplatin-based chemoradiotherapy and subsequent
brachytherapy after which patients will receive additional
doses of pembrolizumab. A phase II study of pembrolizumab
in combination with chemoradiation and brachytherapy in
women with locally advanced cervical cancer is also open for
recruitment (NCT02635360).50 These studies will help assess
whether cell death from ionizing radiation and the release
of tumour antigens can initiate an immunogenic response in
both the irradiated tumour and, potentially, in distant metas-
tases through the abscopal effect.18
Nivolumab (Bristol-Myers Squibb) is a human IgG4 mon-
oclonal antibody that binds to the PD-1 receptor and blocks
its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-
mediated inhibition of the immune response.51 Checkmate
358 (NCT02488759)52 is an ongoing phase I/II in virus-
associated tumours including cervical cancer. Preliminary
data of efficacy and toxicity in patients with recurrent or
metastatic cervical, vaginal, and vulvar cancer (total 24
patients, 19 of whom had cervical cancer) have been reported.
ORR was 20.8% and disease control rate was 70.8%. Responses
were observed regardless of PD-L1 expression, HPV status, and
number of prior therapies. Median PFS was 5.5 mo; median
OS has not yet been reached (median follow-up 31 weeks).
Nivolumab has also been studied in the NRG-GY002, a phase
II study for patients with persistent or recurrent cervical can-
cer (NCT02257528).53 A trial of the combination of nivolumab
with HPV-16 SLP vaccine (ISA 101) in HPV-16 positive tumours
is also recruiting patients (NCT02426892).35
Other checkpoint inhibitors are also under investigation
for cervical cancer treatment. Atezolizumab (Roche) a fully
humanized, engineered monoclonal antibody of IgG1 isotype
PD-L1, is currently under evaluation through the Phase Ib PRO-
LOG study (NCT02914470).54 This study assesses the safety
and tolerability of the combination of atezolizumab with car-
boplatin/cyclophosphamide in both advanced breast cancer
and gynaecological cancer patients including cervical cancer.
A phase II trial of atezolizumab in combination with VigilTM
(Gradalis) is currently recruiting patients with gynaecologi-
cal malignancies, including cervical cancer (NCT03073525).55
Atezolizumab in combination with bevacizumab is under
evaluation in a phase II study with dedicated enrolment
of women with metastatic, recurrent or persistent cervical
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cancer (NCT02921269).56 It is thought that anti-angiogenic
therapy may potentially enhance immunotherapy efficacy due
to the increase in intratumoural T-cell infiltration.57
Another checkpoint inhibitor, durvalumab (Medim-
mune/AstraZeneca), a human IgG1 kappa monoclonal
antibody that blocks the interaction of PD-L1 with the PD-1
and CD80 molecules, is under evaluation in a phase I trial
in combination with Tremelimumab (AstraZeneca) a fully
human monoclonal antibody against CTLA-4 (NCT01975831).
This trial will include patients with cervical cancer that
have failed to respond to or relapsed following standard
treatment.58
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) was the first
immune-checkpoint receptor to be therapeutically targeted.
It is expressed exclusively on T cells and capable of down-
regulating T-cell function to prevent over-activation of the
immune system.18 Ipilimumab (Bristol-Myers Squibb), was
studied in a phase I/II trial in patients with metastatic or
recurrent cervical cancer.59 Forty-two patients were enrolled;
toxicities were manageable and grade 3 toxicities included
diarrhoea and colitis; median PFS was 2.5 months (95% CI:
2.3–3.2). GOG 992960 is a phase I clinical trial investigating the
role of ipilimumab after chemoradiation in patients with node
positive cervical cancer. The trial included 34 patients with
FIGO stage IB2/IIA or IIB/IIIB/IVA cervical cancer and positive
nodes. 19 of the 34 patients were evaluable, all patients com-
pleted chemo-radiotherapy; 90% had 4 cycles of ipilimumab
and the maximum tolerated dose was ipilimumab 10 mg/kg. In
terms of toxicity, majority of the adverse events were grade 1–2
and 16% of the patients experienced grade 3 toxicity includ-
ing lipase increased, neutropenia and rash. 1-year disease free
survival (DFS) was 74%.
2.3. Adoptive cell transfer therapy
Adoptive transfer of tumour-antigen targeting T cells into
a cancer patient, after ex vivo amplification, with or with-
out genetic modification is a promising treatment strategy.
However, limitations include its technological complexity,
labour-intensity and high cost.
Adoptive T-cell therapy involves the ex vivo culture of tumour
specimens and expansion of tumour infiltrating lymphocytes
(TILs). T cells of a preferred antigen-specificity and phenotype
can be identified in vitro and proliferated. These T cells are
infused into autologous tumour-bearing patients after receiv-
ing lymphodepleting chemotherapy agents. The number of
antigen-specific T cells in peripheral blood after this method
usually exceeds by far that possible by current vaccine treat-
ment strategies alone.61 In addition, adoptive T cells appear
more effective in inducing tumour regression than lympho-
cytes generated by vaccines, suggesting greater ability to
overcome tumour-mediated immune evasion mechanisms.62
Nine women with metastatic cervical cancer were enrolled
in a trial that included HPV-related tumours.63 T-cell cul-
tures derived from fragments of metastatic tumour and
expanded using IL-2 were tested for reactivity against the
HPV-16 or HPV18 E6 and E7 antigens. Patients were given a sin-
gle infusion of HPV-reactive tumour-infiltrating T cells. This
was preceded by lymphocyte-depleting chemotherapy and
followed by aldesleukin administration. Three patients
showed objective tumour response and two of these had
a durable complete clinical response that lasted more than
a year (15 and 22 months). Most common toxicities were
haematological and related to the lymphocyte-depleting con-
ditioning regimen. It is suggested that adoptive T-cell therapy
is potentially a viable salvage therapy for metastatic cervical
cancer patients who currently have limited treatment options.
Genetic modification of T cells. Chimeric antigen receptor
(CAR) T-cell therapy involves the ex vivo amplification of autol-
ogous T cells carrying genetically engineered T cell receptors
(TCRs) which are designed to recognize specific tumour anti-
gens. While T cell receptors are restricted in binding by
MHC haplotype, CAR T cells are designed to allow MHC-
independent antigen recognition; these modified T cells are
subsequently re-administered to cancer patients.64 A phase
I study evaluated adoptive CD4+ T-cell therapy with retro-
viral transduction of a T cell receptor that recognized the
melanoma-associated antigen-A3 in patients with metastatic
solid tumour cancers.65 The trial included 2 cervical cancer
patients, one of these patients experienced an objective com-
plete response that in August 2017 had been ongoing for 29
months. A Phase I trial of HPV-16 E7-oncoprotein-targeting
T cell receptor therapy alone or in combination with PD-1
inhibitor Pembrolizumab is currently recruiting patients with
HPV-associated cancers (NCT02858310).66
3. Conclusion and future directions
Diverse immunotherapy strategies are currently under eval-
uation for the treatment of high risk/locally advanced and
recurrent/metastatic cervical cancer. Evidence from phase I
and II clinical trials is encouraging; nonetheless, the optimal
timing for delivering immunotherapy strategies is unclear and
specific predictive biomarkers are lacking.
Screening programmes, sex education and treatment of
pre-malignant lesions should be prioritized, in order to avoid
the development of cervical cancer. The majority of women
affected by this tumour live in countries with poor health care
coverage and limited access to targeted therapy. This requires
careful consideration and dialogue between pharmaceutical
companies, health authorities, the wider scientific commu-
nity, patients and their advocates, in order to improve access
to newer therapies in low- and middle-income countries. The
use of vaccines for the prevention of HPV infection has not
been reviewed in this article. This approach has the potential
to eradicate cervical cancer.
When cervical cancer develops, our efforts should
focus on strategies to avoid relapse. Checkpoint inhibitors
and/or therapeutic vaccines combined with radiotherapy and
chemotherapy are currently been studied in this setting. For
metastatic/relapsed disease, data is encouraging, however,
results from phase III randomized trials are awaited.
Strategies such as adoptive cell therapy warrant further
exploration but the complexity of such treatments limit their
use to specialized centres at present.
In conclusion, immunotherapy for cancer treatment is a
rapidly developing field, proven to be successful in several
tumours. Further randomized clinical trial results are needed.
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Results so far from phase II trials are encouraging, in par-
ticular given the limited efficacy of treatments beyond the
first line. The next steps include the identification of optimal
immunotherapeutic strategies, timing of treatment, manage-
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63. Stevanović S, Draper LM, Langhan MM, et al. Complete
regression of metastatic cervical cancer after treatment with
human papillomavirus-targeted tumor-infiltrating T cells. J
Clin Oncol 2015;33(14):1543–50.
64. Fesnak AD, June CH, Levine BL. Engineered T cells: the
promise and challenges of cancer immunotherapy. Nat Rev
Cancer 2016;16(9):566–81.
65. Lu Y-C, Parker LL, Lu T, et al. Treatment of patients with
metastatic cancer using a major histocompatibility complex
class II-restricted T-cell receptor targeting the cancer
germline antigen MAGE-A3. J Clin Oncol 2017;35(29):3322–9.
66. A phase I trial of T cell receptor gene therapy targeting HPV-16 E7
with or without PD-1 blockade for HPV-associated cancers,
NCT02858310; 2017 [Internet]. Available at:
https://clinicaltrials.gov/ct2/show/NCT02858310 [cited
22.10.17].
